dc.contributor.author | Herrmann, Eva | |
dc.contributor.author | Karayalcin, Selim | |
dc.contributor.author | Flisiak, Robert | |
dc.contributor.author | van 't Veen, Annemarie | |
dc.contributor.author | de Man, Robert A. | |
dc.contributor.author | Schalm, Solko W. | |
dc.contributor.author | Janssen, Harry L. A. | |
dc.contributor.author | Haagmans, Bart L. | |
dc.contributor.author | Cakaloglu, Yilmaz | |
dc.contributor.author | ter Borg, Martijn J. | |
dc.contributor.author | Hansen, Bettina E. | |
dc.contributor.author | Zeuzem, Stefan | |
dc.date.accessioned | 2021-03-04T08:45:06Z | |
dc.date.available | 2021-03-04T08:45:06Z | |
dc.date.issued | 2007 | |
dc.identifier.citation | ter Borg M. J. , Hansen B. E. , Herrmann E., Zeuzem S., Cakaloglu Y., Karayalcin S., Flisiak R., van 't Veen A., de Man R. A. , Schalm S. W. , et al., "Modelling of early viral kinetics and pegylated interferon-alpha 2b pharmacokinetics in patients with HBeAg-positive chronic hepatitis B", ANTIVIRAL THERAPY, cilt.12, sa.8, ss.1285-1294, 2007 | |
dc.identifier.issn | 1359-6535 | |
dc.identifier.other | av_64d4247f-903c-4759-bbc5-0df264d7a8ac | |
dc.identifier.other | vv_1032021 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/70140 | |
dc.description.abstract | Background: Pegylated interferon alpha 2b (PEG-IFN-alpha 2b) is effective for the treatment of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B, although its mechanism of action remains unclear. HBeAg loss is achieved in 36% of patients after one year of PEG-IFN-a2b treatment and combination therapy with lamivudine is not superior to PEG-IFN-alpha 2b monotherapy. | |
dc.language.iso | eng | |
dc.subject | Temel Eczacılık Bilimleri | |
dc.subject | BULAŞICI HASTALIKLAR | |
dc.subject | İmmünoloji | |
dc.subject | Yaşam Bilimleri (LIFE) | |
dc.subject | FARMAKOLOJİ VE ECZACILIK | |
dc.subject | Farmakoloji ve Toksikoloji | |
dc.subject | VİROLOJİ | |
dc.subject | Tıp | |
dc.subject | Sağlık Bilimleri | |
dc.subject | Temel Tıp Bilimleri | |
dc.subject | Mikrobiyoloji ve Klinik Mikrobiyoloji | |
dc.subject | Viroloji | |
dc.subject | Eczacılık | |
dc.subject | Yaşam Bilimleri | |
dc.subject | Temel Bilimler | |
dc.title | Modelling of early viral kinetics and pegylated interferon-alpha 2b pharmacokinetics in patients with HBeAg-positive chronic hepatitis B | |
dc.type | Makale | |
dc.relation.journal | ANTIVIRAL THERAPY | |
dc.contributor.department | Erasmus University Rotterdam , , | |
dc.identifier.volume | 12 | |
dc.identifier.issue | 8 | |
dc.identifier.startpage | 1285 | |
dc.identifier.endpage | 1294 | |
dc.contributor.firstauthorID | 181564 | |